Fibroblast growth factor 21 and its influence on metabolic processes in the human body

Proshchai, Galina A.; Ворохобина, Наталья Владимировна; Zagarskikh, E. Yu.; Partsernyak, S A; Partsernyak, A S

doi:10.21638/11701/spbu11.2018.104

Cited by 2 publications

(1 citation statement)

References 29 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В то же время на животных моделях продемонстрировано профилактическое воздействие агонистов рецепторов FGF21 в отношении развития фиброза почек [21]. Синтез FGF21 происходит преимущественно в печени [22,21,23,24]. При этом у больных НАЖБП также наблюдается повышение уровня FGF21, при этом введение синтетического аналога FGF21 приводит к уменьшению количества жира в клетках печени.…”

unclassified

Chronic kidney disease and non-alcoholic fatty liver disease - new pathogenetic links

Krasner

Осипенко

Холин

et al. 2023

jour

View full text Add to dashboard Cite

This article discusses the association between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). There is ample evidence of an increased risk of CKD in patients with NAFLD. Most researchers attribute to the common risk factors for these two conditions. Currently, in addition to traditional factors associated with CKD and NAFLD, such as components of the metabolic syndrome, the influence of new pathogenetic factors, i. e. endothelial dysfunction, metabolic disorders of fibroblast growth factor-21, pathological activation of the renin-angiotensin system and influence of adiponectin level change are considered. Further examination of these mechanisms will open up new therapeutic options for the treatment of CKD and NAFLD.

show abstract

unclassified